S

Superluminal Medicines

ML-driven design of candidate small molecules

Research Associate - Discovery Biology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeBoston, MA, USAIn-person

About the Job

Requirements

  • A bachelor's degree in biology, Cell Biology, or a related life sciences discipline.
  • At least 1 year of biotechnology or pharmaceutical industry experience.
  • Experience working with 384-well plate-based assay formats.
  • Experience performing routine mammalian cell culture techniques.
  • Experience with plate-based in vitro assays using one or more of HTRF, luminescence, BRET, or Alpha assay technologies.
  • Experience executing cell-based assays, including assay optimization and routine screening campaigns.

Responsibilities

  • Perform routine mammalian cell culture and maintain mammalian cell lines.
  • Execute routine cell-based assays to support early-stage drug discovery programs.
  • Assist with the development and optimization of new cell-based assays for screening under the guidance of the manager.
  • Generate, analyze, document, and upload experimental data to company databases in a timely and accurate manner.
  • Ensure compliance with established laboratory practices, standard operating procedures, and company policies, including wet-lab and electronic data-management requirements.

Desired Qualifications

  • Experience with laboratory automation and/or semi-automated assay workflows.
  • Experience in small molecule drug discovery.

About the Company

Superluminal Medicines

ML-driven design of candidate small molecules

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company size
51-200
Company stage
Series B
Total funding
$213M
Headquarters
Boston, MA
Founded
2023

Recently Posted Jobs

Explore more opportunities at Superluminal Medicines

See more jobs